BRAF and central nervous system cancer: MAPK-driven included PAs with BRAF alterations (BRAFV600E, n = 30; BRAF fusion, n = 38; BRAF MT other, n = 20), diffuse low-grade gliomas with MAPK alterations (n = 1), and rosette-forming glioneuronal tumors (n = 7).